文献速递造血干细胞移植与细胞治疗

环孢素联合吗替麦考酚酯预防无关供者干细胞移植后急性移植物抗宿主病的效果劣于环孢素联合甲氨蝶呤

The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
PubMed 文献 · Am J Hematol · 2017-02-01

该研究分析了472例连续无关供者干细胞移植受者,分别采用环孢素/甲氨蝶呤(MTX,n=314)或环孢素/吗替麦考酚酯(MMF,n=158)预防GVHD。MMF组中性粒细胞植入更快,但急性GVHD II-IV级和III-IV级发生率、非复发死亡率及GVHD相关死亡均高于MTX组;总体生存MTX组更优,但调整患者特征后差异仅处临界显著性(HR 1.3,P=.08)。结论认为环孢素/MMF与更快植入和可能更少的器官毒性相关,但急性GVHD及GVHD相关死亡增加。

要点

  • MMF组急性GVHD II-IV级发生率为47%,MTX组为27%(P<.001)。
  • MMF组非复发死亡率为44%,MTX组为24%(P<.001)。
  • 调整患者特征后总体生存差异仅处临界显著性(HR 1.3,P=.08)。

核心结论

  • 环孢素/MMF与更快植入和可能更少的器官毒性相关,但急性GVHD及GVHD相关死亡增加。

研究设计与样本

  • 分析472例连续无关供者干细胞移植受者,环孢素/MTX组314例,环孢素/MMF组158例。
  • 采用类意向性治疗分析以减少潜在选择偏倚,并比较2008-2009年(MMF占89%)与其他时期(MTX占82%)的移植结局。

主要发现

  • 中性粒细胞植入MMF组更快,分别为第11天和第14天(P=.001)。
  • 急性GVHD II-IV级和III-IV级在MMF组分别为47%和28%,MTX组分别为27%和12%(P<.001)。
  • 非复发死亡率MMF组为44%,MTX组为24%(P<.001)。
  • GVHD相关死亡MMF组为25%,MTX组为8%(P<.0001);其他非复发死亡原因分别为19%和16%(P=.39)。
  • 总体生存MTX组更优,分别为40%和29%(P=.006);调整患者特征后差异仅处临界显著性(HR 1.3,P=.08)。

关键数值与推荐

  • 急性GVHD II-IV级:MMF组47% vs MTX组27%(P<.001)。
  • 急性GVHD III-IV级:MMF组28% vs MTX组12%(P<.001)。
  • 非复发死亡率:MMF组44% vs MTX组24%(P<.001)。
  • GVHD相关死亡:MMF组25% vs MTX组8%(P<.0001)。
  • 总体生存:MMF组29% vs MTX组40%(P=.006);调整后HR 1.3(P=.08)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (GVHD) is the major treatment-related complication after stem-cell transplantation (SCT) from unrelated-donors. Several GVHD prophylaxis regimens have been explored, but no regimen has shown superiority. We analyzed transplantation outcomes in 472 consecutive unrelated-donor SCT recipients, using cyclosporine/methotrexate (MTX, n = 314) or cyclosporine/mycophenolate-mofetil (MMF, n = 158) for GVHD prophylaxis. Neutrophil engraftment was faster after MMF, days 11 and 14, respectively (P = .001). Acute GVHD grade II-IV and III-IV occurred in 47% and 28% after MMF compared to 27% and 12% after MTX, respectively (P < .001). Nonrelapse mortality (NRM) was 44% and 24%, respectively (P < .001). Death associated with GVHD occurred in 25% and 8% (P < .0001), while other NRM causes occurred in 19% and 16%, respectively (P = .39). Relapse mortality was similar. Overall survival was better after MTX, 40% and 29%, respectively (P = .006). However, this difference had only borderline significance when adjusting for differences in patient characteristics (HR, 1.3, P = .08). To minimize potential selection bias we analyzed outcomes on the basis of an intention-to-treat like analysis. During the years 2008-2009, the leading GVHD prophylaxis regimen for unrelated-donor SCT included MMF (89% of transplants). During the other periods, MTX was used predominantly (82% of transplants). The two periods were otherwise well-matched. Acute GVHD occurred more often in 2008-2009. Death associated with GVHD occurred more often, while other NRM causes occurred less often resulting in similar NRM and overall survival. In conclusion, cyclosporine/MMF is associated with faster engraftment and possibly with less organ toxicity than cyclosporine/MTX. However, it is associated with increased rates of acute GVHD and GVHD-associated deaths.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Yerushalmi R, Shem-Tov N, Danylesko I, et al. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Am J Hematol. 2017. PMID: 28052467. doi:10.1002/ajh.24631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。